SCHEMBL12875697

SCHEMBL12875697

Cc1cccc(-c2csc(Cn3ncc(C(=O)O)c3C)n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT5 Q9NXA8 2/20 0.44
AKT1 P31749 2/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
KLKB1 P03952 1/20 0.42
KLK1 P06870 1/20 0.42
AKR1B1 P15121 1/20 0.41
ATP4A P20648 2/20 0.41
ATP4B P51164 2/20 0.41
KMO O15229 2/20 0.41
GRIN2B Q13224 1/20 0.41
ITGB3 P05106 1/20 0.41
ITGA2B P08514 1/20 0.41
PTGER4 P35408 1/20 0.40
PTPRF P10586 1/20 0.39
PTPN2 P17706 1/20 0.39
PTPN1 P18031 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HDAC3 O15379 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875696 0.88 KMT2A (0.53) AKT1KDM4EALDH1A1GRIN2BITGB3
SCHEMBL1197463 0.87 ITGB2 (0.52) SIRT5KDM4EALDH1A1ITGB3ITGA2B
SCHEMBL12876353 0.86 NFE2L2 (0.42) SIRT5AKT1KDM4EALDH1A1AKR1B1
SCHEMBL1198469 0.85 KDM4E (0.44) KDM4EALDH1A1MEN1KMT2AGFER
SCHEMBL1198911 0.84 MEN1 (0.52) KDM4EMEN1KMT2A
SCHEMBL12875689 0.80 KMO (0.47) AKT1AKR1B1KMO
SCHEMBL12875489 0.79 KDM4E (0.60) SIRT5KDM4EALDH1A1ITGB3ITGA2B
SCHEMBL12875682 0.79 SIRT5 (0.44) SIRT5AKT1KDM4EALDH1A1KLKB1
SCHEMBL12876343 0.78 NPC1 (0.41) SIRT5AKT1KDM4EALDH1A1ATP4A
SCHEMBL1198442 0.76 KDM4E (0.56) KDM4EALDH1A1ITGB3ITGA2BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed
WO-2009123316-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF 武田薬品工業株式会社 (JP) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A SIRT5 531/4885AKT1 402/4885KDM4E 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.